USANA HEALTH SCIENCES INC USNA

Healthcare SIC 2833 - Medicinal Chemicals & Botanical Products NAICS Manufacturing › Chemical Manufacturing › Pharmaceutical and Medicine Manufacturing › Medicinal and Botanical Manufacturing derived NYSE

USANA Health Sciences, Inc. develops and manufactures high-quality nutritional supplements, functional foods and personal care products that are sold throughout the world. In 2025, we generated $925 million in net sales and finished the year with approximately 387,000 active Customers in our core nutritional business. We were founded in 1992 by Myron W. Wentz, Ph.D. and since that time, we have developed and manufactured high quality, science-based nutritional, personal care and skincare products with a primary focus on promoting long-term health and wellness. We are committed to continuous product innovation and sound scientific research. We have operations in 25 geographic markets worldwide. Historically, we have distributed our products through the direct selling channel, because we believe it is conducive to our vision of improving the overall health and nutrition of individuals and families around the world. Mainland China ("China") is our largest market and single largest source of revenue, representing approximately 41.3% of net sales and approximately 49.9% of core nutritional active Customers. As a U.S.-based multi-national corporation with an expanding international presence, our operating results are sensitive to currency fluctuations, as well as economic and political conditions in markets throughout the world. Additionally, we are subject to the various laws and regulations in the United States, China, and the other markets in which we operate with respect to the products that we manufacture, and sell, and our method of distribution. We are a U.S. public company listed on the New York Stock Exchange ("NYSE") and subject to the rules of the SEC.

Last close 13.96 2026-10-23
Market cap $257.9M 2026-07-04 share count
52-week range 12.57 - 23.59

Valuation FY2025 figures against the last close

P/S0.3x
P/E24.1x
P/FCF30.3x
EV/EBITDA3.7x
Dividend yield—
Diluted EPS0.58

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue $925.3M$854.5M$921.0M$998.6M$1.19B$1.13B$1.06B$1.19B$1.05B$1.01B
Cost of revenue $200.9M$161.2M$176.7M$193.9M$217.9M$209.1M$187.5M$200.7M$179.4M$180.2M
Gross profit $724.4M$693.3M$744.3M$804.7M$968.6M$925.5M$873.4M$988.5M$867.9M$825.9M
R&D $10.7M$11.6M$11.4M$11.6M$11.1M$10.6M$10.3M$10.2M$9.0M$8.8M
SG&A $337.4M$263.3M$257.0M$262.3M$279.1M$261.2M$267.7M$275.1M$265.1M$234.2M
Total operating expenses $687.0M$627.0M$651.2M$697.1M$798.4M$749.0M$727.2M$800.2M$735.4M$687.3M
Operating income $37.4M$66.3M$93.1M$107.6M$170.2M$176.5M$146.2M$188.4M$132.5M$138.6M
Interest expense $842.0K$281.0K$262.0K$192.0K$57.0K$507.0K$66.0K$36.0K$46.0K$444.0K
Pre-tax income $41.5M$76.4M$102.5M$108.6M$170.6M$177.9M$150.5M$191.5M$134.6M$138.6M
Income tax $30.1M$34.3M$38.7M$39.3M$54.1M$53.3M$50.0M$65.3M$72.1M$38.5M
Net income $10.8M$42.0M$63.8M$69.3M$116.5M$124.7M$100.5M$126.2M$62.5M$100.0M
EPS, basic 0.582.203.313.605.785.894.445.242.574.14
EPS, diluted 0.582.193.303.595.735.864.415.122.533.99
Shares, diluted (wtd. avg.) 18.6M19.2M19.3M19.3M20.3M21.3M22.8M24.6M24.7M25.0M

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents $158.4M$181.8M$330.4M$288.4M$239.8M$311.9M$234.8M$214.3M$247.1M$179.0M
Inventory $102.6M$69.7M$61.5M$67.1M$98.3M$98.3M$68.9M$81.9M$62.9M$64.8M
Total current assets $288.4M$279.2M$417.7M$384.4M$365.1M$425.3M$329.3M$392.3M$340.2M$277.9M
Property, plant and equipment $94.4M$94.6M$99.8M$97.8M$101.8M$100.4M$95.2M$92.0M$102.8M$101.3M
Goodwill $138.0M$144.2M$17.1M$17.4M$17.7M$17.4M$16.6M$16.8M$17.4M$16.7M
Other intangibles $133.2M$151.8M$29.9M$32.4M$30.4M$30.8M$29.8M$31.8M$35.2M$34.3M
Total assets $742.9M$748.2M$632.8M$596.5M$577.7M$640.9M$516.9M$554.5M$519.3M$470.6M
Accounts payable $17.3M$12.0M$10.1M$11.0M$13.5M$18.2M$12.5M$9.9M$11.8M$9.0M
Total current liabilities $128.6M$139.6M$118.8M$143.8M$160.8M$168.1M$136.1M$148.7M$141.2M$138.5M
Total liabilities $156.6M$161.9M$135.6M———————
Retained earnings $465.7M$478.9M$445.2M$391.6M$344.6M$382.8M$306.1M$329.5M$288.1M$265.4M
Total equity $533.1M$532.1M$497.2M$434.5M$395.1M$441.6M$351.7M$391.1M$363.2M$325.3M

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Operating cash flow $22.3M$61.0M$70.6M$103.9M$121.2M$160.4M$126.7M$152.1M$123.8M$136.9M
Depreciation and amortisation $32.6M$14.5M$12.7M$13.4M$13.0M$13.7M$14.7M$16.8M$16.1M$13.5M
Stock-based compensation $13.8M$14.6M$14.6M$13.3M$14.3M$14.4M$15.5M$15.0M$15.5M$16.5M
Capital expenditure $13.8M$10.1M$14.5M$10.4M$12.8M$15.1M$16.6M$11.4M$13.2M$32.7M
Investing cash flow -$10.1M-$213.1M-$12.0M-$12.4M-$14.2M-$34.0M$47.5M-$69.0M-$12.9M-$31.9M
Financing cash flow -$40.6M$9.6M-$14.2M-$30.1M-$181.4M-$59.4M-$152.1M-$105.3M-$50.3M-$64.9M
Buybacks $27.5M$9.4M$11.6M$25.4M$177.8M$57.0M$150.0M$105.4M$50.0M$64.6M

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0000896264-26-000026.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. 0 500M 1B 1.5B Revenue, FY2016: 1B Gross profit, FY2016: 825.9M Net income, FY2016: 100M Revenue, FY2017: 1B Gross profit, FY2017: 867.9M Net income, FY2017: 62.5M Revenue, FY2018: 1.2B Gross profit, FY2018: 988.5M Net income, FY2018: 126.2M Revenue, FY2019: 1.1B Gross profit, FY2019: 873.4M Net income, FY2019: 100.5M Revenue, FY2020: 1.1B Gross profit, FY2020: 925.5M Net income, FY2020: 124.7M Revenue, FY2021: 1.2B Gross profit, FY2021: 968.6M Net income, FY2021: 116.5M Revenue, FY2022: 998.6M Gross profit, FY2022: 804.7M Net income, FY2022: 69.3M Revenue, FY2023: 921M Gross profit, FY2023: 744.3M Net income, FY2023: 63.8M Revenue, FY2024: 854.5M Gross profit, FY2024: 693.3M Net income, FY2024: 42M Revenue, FY2025: 925.3M Gross profit, FY2025: 724.4M Net income, FY2025: 10.8M FY2016 FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue $1.01B $1.05B $1.19B $1.06B $1.13B $1.19B $998.6M $921.0M $854.5M $925.3M
Gross profit $825.9M $867.9M $988.5M $873.4M $925.5M $968.6M $804.7M $744.3M $693.3M $724.4M
Net income $100.0M $62.5M $126.2M $100.5M $124.7M $116.5M $69.3M $63.8M $42.0M $10.8M

Recent filings and events

  • Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
  • Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
  • Shareholder vote The results of the annual meeting or a special vote. Item 5.07
  • Results announced Item 2.02
  • Regulation FD disclosure Item 7.01
  • Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
  • Results announced Item 2.02
  • Regulation FD disclosure Item 7.01
  • Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
  • Results announced Item 2.02
  • Regulation FD disclosure Item 7.01
  • Officer or director change Item 5.02

Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.

Others in SIC 2833

TickerCompanyMarket capP/ERevenue growth
DFTX Definium Therapeutics, Inc. $4.79B — —
TRLV Trulieve Cannabis Corp. $2.01B — -0.4%
CRON Cronos Group Inc. $1.23B — 24.6%
TLRY Tilray Brands, Inc. $382.7M — 11.5%
CGC Canopy Growth Corp $285.9M — —
NAGE Niagen Bioscience, Inc. $192.3M 12.2x 29.9%
FTLF FITLIFE BRANDS, INC. $78.4M 13.3x 26.4%
BTMD biote Corp. $30.6M 1.4x -2.5%